Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.36 |
| ▸ | HSD17B3 | P37058 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22149253 | 0.80 | MEN1 (0.44) | CYP3A4KMT2AMEN1GLAHSD17B3 | |
| SCHEMBL22149723 | 0.80 | MEN1 (0.44) | CYP3A4KMT2AMEN1GLAHSD17B3 | |
| SCHEMBL22149726 | 0.77 | MAPT (0.41) | CYP3A4KMT2AMEN1GLAAAK1 | |
| SCHEMBL22149282 | 0.77 | MAPT (0.41) | CYP3A4KMT2AMEN1GLAAAK1 | |
| SCHEMBL22149728 | 0.73 | CYP3A4 (0.44) | CYP3A4KMT2AMEN1GLAAAK1 | |
| SCHEMBL25964843 | 0.73 | CYP3A4 (0.44) | CYP3A4KMT2AMEN1GLAAAK1 | |
| SCHEMBL22149548 | 0.69 | MAPT (0.37) | KMT2AMEN1GLAKDM4EALDH1A1 | |
| SCHEMBL12261087 | 0.66 | AAK1 (0.37) | AAK1TDP1KDM4EMAPT | |
| SCHEMBL2573803 | 0.65 | CYP3A4 (0.56) | CYP3A4KMT2AMEN1GLAHSD17B3 | |
| SCHEMBL8886719 | 0.65 | CYP3A4 (0.50) | CYP3A4KMT2AMEN1GLAHSD17B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898613-B1 | ANTICANCER COMPOUNDS | PHARMA MAR SA (ES) | 2023-08-09 | — | — | EP | disclosed |
| US-20220056021-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2022-02-24 | — | — | US | disclosed |
| WO-2020127194-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056021-A1 | ANTICANCER COMPOUNDS | TP53, MCL1, MYC | CYP3A4 1151/4885KMT2A 3314/4885MEN1 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.